Patents by Inventor Janine Schuurman

Janine Schuurman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASE
    Publication number: 20200123237
    Abstract: The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding.
    Type: Application
    Filed: May 17, 2017
    Publication date: April 23, 2020
    Applicant: Genmab B.V.
    Inventors: Annemarie KUIPERS, Kok van KESSEL, Frank BEURSKENS, Rob de JONG, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN, Jos van STRIJP, Suzan ROOIJAKKERS
  • Heterodimeric antibody Fc-containing proteins and methods for production thereof
    Patent number: 10597464
    Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: March 24, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
  • Bispecific EGFR/C-Met Antibodies
    Publication number: 20200087407
    Abstract: Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Inventors: Mark Chiu, Sheri Moores, Joost Neijssen, Paul Parren, Janine Schuurman
  • Inert format
    Patent number: 10590206
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: March 17, 2020
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
  • MONOCLONAL ANTIBODIES AGAINST C-MET
    Publication number: 20200079872
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: August 23, 2019
    Publication date: March 12, 2020
    Inventors: Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
  • PRODUCTION OF HETERODIMERIC PROTEINS
    Publication number: 20200048304
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: May 30, 2019
    Publication date: February 13, 2020
    Inventors: Michael GRAMER, Amitava KUNDU, Ewald T. J. VAN DEN BREMER, Muriel VAN KAMPEN, Patrick PRIEM, Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Janine SCHUURMAN, Paul PARREN, Patrick VAN BERKEL, Werner L. VOS, Arnout F. GERRITSEN
  • Bispecific antibodies against CD3 and CD20
    Patent number: 10544220
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 28, 2020
    Assignee: GENMAB A/S
    Inventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
  • VARIANTS OF CD38 ANTIBODY AND USES THEREOF
    Publication number: 20200017600
    Abstract: Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
    Type: Application
    Filed: July 15, 2019
    Publication date: January 16, 2020
    Inventors: Bart De GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
  • Humanized or chimeric CD3 antibodies
    Patent number: 10465006
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: November 5, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Paul Parren
  • ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190315877
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: Marije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20190284278
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: July 14, 2016
    Publication date: September 19, 2019
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • POLYPEPTIDE VARIANTS AND USES THEREOF
    Publication number: 20190276549
    Abstract: Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.
    Type: Application
    Filed: November 1, 2017
    Publication date: September 12, 2019
    Applicant: GENMAB B.V.
    Inventors: Rob DE JONG, Frank BEURSKENS, Marije OVERDIJK, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
  • Humanized or chimeric CD3 antibodies
    Patent number: 10407501
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 10, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • Recombinant IgG4 monovalent antibodies
    Patent number: 10351629
    Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 16, 2019
    Assignee: GENMAB A/S
    Inventors: Janine Schuurman, Tom Vink, Jan Van De Winkel, Aran Frank Labrijn, Paul Parren, Willem Karel Bleeker, Frank Beurskens, Patrick Van Berkel
  • Production of heterodimeric proteins
    Patent number: 10344050
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: July 9, 2019
    Assignee: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
  • ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190202926
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Application
    Filed: December 1, 2016
    Publication date: July 4, 2019
    Inventors: Frank BEURSKENS, Marije OVERDIJK, Rob DE JONG, David SATIJN, Kristin STRUMANE, Janine SCHUURMAN, Paul PARREN
  • RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20190169298
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Application
    Filed: November 7, 2018
    Publication date: June 6, 2019
    Inventors: Paul PARREN, Janine SCHUURMAN, Tom VINK, Willem Karel BLEEKER, Jan VAN DE WINKEL, Patrick VAN BERKEL, Frank BEURSKENS
  • ANTI-DR5 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190144554
    Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
    Type: Application
    Filed: December 1, 2016
    Publication date: May 16, 2019
    Inventors: Marije OVERDIJK, Kristin STRUMANE, Rik RADEMAKER, Esther BREIJ, Janine SCHUURMAN, Paul PARREN
  • Recombinant monovalent antibodies and methods for production thereof
    Patent number: 10155816
    Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: December 18, 2018
    Assignee: GENMAB A/S
    Inventors: Paul Parren, Janine Schuurman, Tom Vink, Willem Karel Bleeker, Jan Van De Winkel, Patrick Van Berkel, Frank Beurskens
  • ANTIBODY VARIANTS HAVING MODIFICATIONS IN THE CONSTANT REGION
    Publication number: 20180319888
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Application
    Filed: May 11, 2018
    Publication date: November 8, 2018
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters